Achieve Life Sciences Q2 2026: $74.8M Net Loss, $187.3M Cash, and NDA Resubmission Set for Q4 2026
ACHV has more than doubled off its 52-week low of $2.371.
Summary
Achieve Life Sciences reported a Q2 net loss of $74.8M, including a $48.7M non-cash warrant liability adjustment, and held $187.3M in cash. The company plans to resubmit its cytisinicline NDA in Q4 2026 after addressing manufacturing issues, with potential FDA approval in H1 2027.
Key Events · Earnings and Guidance · ACHV
-
Q2 2026 Financial Results
Net loss of $74.8M, including a $48.7M non-cash charge from warrant liability fair value change. Cash and equivalents of $187.3M as of June 30, 2026.
-
Regulatory Path Forward
FDA Complete Response Letter received June 20, 2026, cited manufacturing observations but no efficacy or safety issues. NDA resubmission planned for Q4 2026 with new U.S. manufacturer Adare Pharma Solutions; potential approval in H1 2027.
-
Leadership and Board Strengthened
New CEO Andrew Goldberg, MD, appointed; commercial team hires from Verona Pharma; six new board members added, including representatives from TPG and venBio.
-
Private Placement Closed
Closed a private placement of up to $354M ($180M upfront, up to $174M from milestone-based warrants). Proceeds to fund Phase 3 trial, commercialization, and working capital.
Analysis · ACHV · Life Sciences
A $48.7 million non-cash charge from warrant liability revaluation drove Achieve Life Sciences' Q2 net loss to $74.8 million—not an operational cash drain. With $187.3 million in cash at quarter-end, the company has runway into 2027. The FDA's Complete Response Letter raised no efficacy or safety concerns, and the NDA resubmission is planned for Q4 2026 with a new U.S. manufacturer, targeting potential approval in the first half of 2027. The filing also details a strengthened leadership team and board, positioning the company for a commercial launch if approved.
At the time of this filing, ACHV was trading at $6.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $695M. The 52-week trading range was $2.37 to $7.11. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.